Key terms
About APTO
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest APTO news
Apr 03
7:06am ET
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Mar 28
7:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 27
5:05pm ET
Aptose Biosciences’ Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Mar 26
4:38pm ET
Aptose Biosciences Expands AML Treatment Trials
Mar 26
4:15pm ET
Aptose Biosciences proceeds from closing of public offering Jan 30 $9.7M
Mar 26
4:12pm ET
Aptose Biosciences reports FY23 EPS ($7.58) vs ($6.80) last yeat
Mar 18
5:07pm ET
Aptose Biosciences Unveils Upcoming Financials
Mar 18
5:04pm ET
Aptose Biosciences Clarifies Regulatory Compliance Measures
Feb 01
9:00am ET
Aptose Biosciences price target lowered to $5 from $12 at Piper Sandler
Feb 01
8:09am ET
Piper Sandler Sticks to Its Buy Rating for Aptose Biosciences (APTO)
Jan 27
4:06am ET
Aptose Biosciences Issues Regulation FD Disclosure Statement
Jan 26
8:08am ET
Aptose Biosciences prices 4.9M shares at $1.71 in underwritten public offering
No recent press releases are available for APTO
APTO Financials
Key terms
Ad Feedback
APTO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
APTO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
